Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113028 - COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

Publication Number WO/2020/113028
Publication Date 04.06.2020
International Application No. PCT/US2019/063640
International Filing Date 27.11.2019
IPC
C07C 211/44 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
211Compounds containing amino groups bound to a carbon skeleton
43having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
44having amino groups bound to only one six-membered aromatic ring
A61K 31/41 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4164 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
C07C 211/43 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
211Compounds containing amino groups bound to a carbon skeleton
43having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07D 263/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
263Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
02not condensed with other rings
30having two or three double bonds between ring members or between ring members and non-ring members
CPC
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 229/60
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
229Compounds containing amino and carboxyl groups bound to the same carbon skeleton
52having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
54with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
60with amino and carboxyl groups bound in meta- or para- positions
C07C 237/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
28having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
30having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
C07C 2601/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2601Systems containing only non-condensed rings
12with a six-membered ring
14The ring being saturated
C07C 2603/74
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2603Systems containing at least three condensed rings
56Ring systems containing bridged rings
58containing three rings
70containing only six-membered rings
74Adamantanes
C07D 263/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
263Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
02not condensed with other rings
30having two or three double bonds between ring members or between ring members and non-ring members
Applicants
  • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US]/[US]
Inventors
  • STOCKWELL, Brent R.
  • ZASK, Arie
  • TAN, Hui
  • DANIELS, Jacob
Agents
  • YANG, Ke
Priority Data
62/771,84127.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS
(FR) COMPOSÉS, COMPOSITIONS ET MÉTHODES DE MODULATION DE LA FERROPTOSE ET DE TRAITEMENT DE TROUBLES EXCITOTOXIQUES
Abstract
(EN)
The present disclosure provides, inter alia, a compound having the structure (1). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.
(FR)
La présente invention concerne entre autres un composé ayant la structure (1). Ladite invention concerne également des compositions contenant un véhicule de qualité pharmaceutique et un ou plusieurs composés. Ladite invention concerne en outre des méthodes de traitement ou d'amélioration des effets d'un trouble excitotoxique chez un sujet, des méthodes de modulation de la ferroptose chez un sujet, des procédés de réduction de l'espèce d'oxygène réactif (ROS) dans une cellule, des méthodes de traitement ou d'amélioration des effets d'une maladie neurodégénérative, des méthodes pour soulager les effets secondaires chez un sujet subissant une radiothérapie et/ou une immunothérapie, et des méthodes de traitement ou d'amélioration des effets d'une infection associés à la ferroptose chez un sujet.
Latest bibliographic data on file with the International Bureau